May 20th 2024
The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Shah Discusses KEYNOTE-180 and BRIGHTER Results in GI Cancers
September 5th 2018Manish A. Shah, MD, discusses key details of the KEYNOTE-180 trial, as well as results from the BRIGHTER study. He also shared his insights on the unanswered questions that still need to be addressed in the field.
Read More
An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic Cancer
September 5th 2018Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
Watch
Nivolumab-Based Therapy Shows Promise in Esophagogastric Cancer
September 4th 2018According to findings from the CheckMate-032 trial, clinically meaningful and durable antitumor activity was found with nivolumab (Opdivo) alone and nivolumab plus ipilimumab in heavily-pretreated patients with esophagogastric cancer.
Read More
Biomarker Development Is Key to the Future of Precision Oncology
August 21st 2018No one doubts that molecular testing has rapidly improved care for patients with colorectal cancer, Stanley R. Hamilton, MD, told his audience at the 2nd Annual International Congress on Oncology Pathology.
Read More
Presence of MSI-H, MMR-D Predicts Lynch Syndrome Across Tumor Types
August 16th 2018Results from a prospective study involving 15,045 tumor samples that underwent next-generation sequencing using MSK-IMPACT and microsatellite-instability testing demonstrate that MSI-high and DNA mismatch-repair deficient tumors are predictive of Lynch syndrome across all tumor types. The results suggest that LS-associated cancers may be more heterogeneous than previously suspected.
Read More
Current Role of Chemotherapy in GI and Colorectal Cancer
August 15th 2018John L. Marshall, MD, chief of the Division of Hematology/Oncology at Medstar Georgetown University Hospital, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the use of chemotherapy in patients with colorectal or other gastrointestinal cancers. He also highlights the importance of understanding each individual patient’s needs before making a treatment decision.
Watch
TAS-120 Demonstrates Promising Results in Cholangiocarcinoma
August 8th 2018Patients with cholangiocarcinoma harboring <em>FGFR2 </em>gene fusions, including patients who had progressed on an FGFR inhibitor, saw a clinically meaningful benefit with TAS-120, according to phase I results presented at the 2018 World Congress on GI Cancer.
Read More
Novel Triplet Regimen for mCRC Granted Breakthrough Designation by FDA
August 7th 2018The triplet combination of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab has been granted a breakthrough therapy designation by the FDA for the treatment of patients with <em>BRAF</em> V600E–mutant metastatic colorectal cancer following 1 or 2 prior lines of treatment in the metastatic setting. The designation will expedite the development and review of the novel triplet in this setting.
Read More
Adding SIRT Does Not Result in Survival Improvement for Patients With HCC
August 7th 2018Compared with sorafenib (Nexavar) alone, sorafenib in combination with selective internal radiation therapy did not provide a significant survival improvement for patients with advanced hepatocellular carcinoma, according to results from the palliative cohort of the SORAMIC trial presented at the 2018 World Congress on Gastrointestinal Cancer in Barcelona, Spain. However, overall survival improvements were seen with the combination in select subgroup analyses.
Read More
Establishing Partnerships to Bring Virtual Tumor Boards to Community Cancer Centers
August 6th 2018The Gene Upshaw Memorial Tahoe Forest Cancer Center has established a cancer care model to address disparities in lung cancer in rural areas. By partnering with the UC Davis Comprehensive Cancer Center and their UC Davis Cancer Care Network, they have been able to address a large issue in cancer care, where 20% of the American population is living in a rural area without access to a National Cancer Institute-designated cancer center.
Read More
Current Treatment Landscape for Pancreatic Cancer
August 3rd 2018Diane Simeone, MD, director of the Pancreatic Cancer Center and associate director of Translational Research at NYU Langone’s Perlmutter Cancer Center, discusses the current state of the pancreatic cancer treatment paradigm. She says it is a very exciting time for this field as there is a large body of researchers now involved.
Watch
Trastuzumab Biosimilar Receives Approval in Europe for Breast and Gastric Cancers
August 2nd 2018The European Union has approved PF-05280014 (Trazimera), a biosimilar for trastuzumab (Herceptin), to treat patients with HER2 overexpressing metastatic or early breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
Atezolizumab Combo Granted Breakthrough Therapy Designation by FDA for Frontline HCC
July 19th 2018Atezolizumab (Tecentriq) has been granted a breakthrough therapy designation by the FDA for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma.
Read More
Kim Highlights Growing Treatment Options for GI Cancers Based on 2 Case Scenarios
July 16th 2018Richard Kim, MD, recently shared his treatment considerations and decisions he makes when treating patients with hepatocellular carcinoma and colorectal cancer. Kim explained his treatment decisions based on 2 gastrointestinal case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives program.
Read More